SASTA OLIPHANT SCIENCE AWARDS

SOUTH AUSTRALIAN SCIENCE TEACHERS ASSOCIATION

Prize Winner

Science Writing

Year 11-12

Angus Smith

Kangaroo Island Community Education

0278-021

Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy – Engineering of T Cells for Cancer Treatment

Research Question: How has the engineering of T cells for cancer treatment, particularly in the context of Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy, benefited society?

Introduction and Scientific Background

Cancer has persisted for millions of years in the cells of animals (*Faguet, 2014*), is a leading cause of death in humans (*Centers for Disease Control and Prevention, 2024*) – and remains an utmost research priority for the medical industry in contemporary society. 'Cancer' is an umbrella term, which refers to the abnormal proliferation of cells within the human body stemming from the mutation of hundreds of different genes. Cancer cells do not respond appropriately to signals that regulate normal cell behaviour (*Cooper, 2000*). This unregulated and continuous cell division leads to the development of malignant tumours, which spread further and interfere with essential bodily components such as nerves, blood vessels and organs. From this, vital functions are impaired and fatal consequences ensue. Importantly, cancer is extremely difficult to combat. Cancer exists in over 200 forms, and by nature has a high rate of mutation (Aubusson et al., 2023). As such, no single treatment can be devised and applied to all cancers (Aubusson et al., 2023). The dubious nature of cancer treatment demands extensive global research. Presently, cancer is combatted with methods such as chemotherapy, hormone therapy and radiation therapy. Chimeric Antigen Receptor (CAR-T) T Cell therapy is an emerging technology that has attracted the attention of scientists internationally (*Kandra et al., 2022*). CAR-T is a customised therapy, involving T Cells (*National Cancer Institute, 2022*). T Cells are a form of white blood cell called lymphocytes (*Cleveland Clinic, 2023*), involved in protecting the body from infection and fighting cancer. Initially in CAR-T therapy, T Cells are collected from the patient and re-engineered in a laboratory to produce proteins on the surface of the cell, called chimeric antigen receptors. These proteins can recognise specific antigens bound to cancer cells, where the T Cells can bind to and subsequently kill the cancer (*National Cancer Institute, 2022*). Researchers have **communicated** and **collaborated** effectively to review this technology, assimilating data from a variety of sources – not only providing a reference point for future studies, but potentially reducing manufacturing costs and increasing distribution availability (*Yu, W; Hua, Z; 2019*). Researches have also reviewed and identified the potential **applications** of CAR-T therapy, as well is its **limitations** and associated qualms regarding its viability (*Kandra et al. 2022*).

Communication and Collaboration

To analyse the efficacy and safety of CAR-T cell therapy and to contrast results in haematological malignancies and solid tumours, researchers have systematically reviewed 997 tumour patients from an assortment of studies. In a meta-analysis and sub-group analysis, Yu & Hua (2019) examined several areas of performance within CAR-T therapy from 52 distinct studies, sourcing from a range of databases such as PubMed, Web of Science and Wanfang. Utilising collaboration, Yu & Hua (2019) were able to synthesise information from various sources to create a viable report, addressing concerns surrounding the effectiveness and safety of CAR-T therapy. Despite lacking direct communication between discrete parties, the report involved the application of data from differing sources for the review and verification of results. In terms of outcomes – overall response rate (ORR; rate of overall reduction in tumour size), complete response rate (CRR; rate of complete eradication of cancer cells), common side effect rate (CSER), and relapse rate (RR; cancer recurrence post-remission) were investigated, providing a scope into the success of treatment.

From the synthesised data it was confirmed that CAR-T therapy had a higher ORR and CRR in haematological malignancies than in solid tumours. The CSER was also higher in haematological malignancies than in solid tumours, and the RR was similar (*Yu, W; Hua, Z; 2019*). Results also indicated that cells cultured without the addition of Interleukin 2 (IL-2; a protein responsible for regulation of lymphocytes including T cells) produced higher ORR – and additionally, administration of less than 10^8 cells elicited higher CRR (*Yu, W; Hua, Z; 2019*). From this assortment of results, there are several benefits. Yu & Hua (2019) stated that the report offers a reference point for prospective research. Additionally, specifications (in terms of IL-2 and optimal number of cells [$<10^8$] for therapy administration) were recommended for manufacturing and clinical treatment. This may lower costs, due to reduced material demand – rendering CAR-T amplification cheaper and allowing treatment of more patients. Overall, Yu & Hua (2019) have exercised communication and collaboration to review existing data surrounding CAR-T cell therapy, providing a reference point for future researchers who endeavour in CAR-T therapy. Omission of the protein IL-2 and administration of less cells in treatment is plausible, reducing costs and increasing the patient number threshold. This case demonstrates the importance of effective communication and collaboration, especially in the ongoing battle with cancer that demands ample research which cannot be satisfied by independent programs. Through synthesising information from external sources, Yu & Hua (2019) have advanced biological grasp of CAR-T cell therapy, as well as preserved human capital for the benefit of society.

Application and Limitation

Upon recognising the vast possibilities of CAR-T therapy, Kandra et al. (2022) reviewed the plausible applications, as well as the societal implications of this technology in lung cancer treatment. Research efforts concluded that CAR-T therapy is a pioneering immunotherapy with qualities superior to that of contemporary technologies – however, existing challenges regarding this treatment impede widespread clinical standardisation. In order to jump these hurdles in the technology's development, various strategies have been considered and/or implemented (*Kandra et al., 2022*). In terms of synthetic CAR function, CARs recognise specific tumour associated antigens, activating genetically engineered T-Cells in order to combat them. Of the components of CARs, the extracellular antigen binding domain (an antibody fragment), recognises antigens of the tumour, triggering downstream signalling pathways which elicit cell response. The hinge/spacer region, a sequence of amino acids, provides flexibility for the T-Cell to achieve ideal distances between it and tumour antigens. The transmembrane domain anchors the CAR to the membrane, providing stability – and the intracellular signalling domain facilitates T-Cell activation. Kandra et al. discussed the prospective employment of CAR-T therapy in various cancers including lung cancer. Presently used technologies possess inadequate efficacy, amounting to substandard clinical outcomes. For instance, poor survival occurs for over 70% of lung cancer patients, even following early diagnosis. Hence, novel developments such as CAR-T therapy must be applied to urgent areas where medical research is insufficient. This is particularly applicable, given recent success from a study assessing 103 patients subject to CAR-T therapy for treatment of haematological malignancies. 76% of said patients experienced remission (*Johnson, 2023*). Though, despite notable effectiveness of CAR-T therapy in haematological malignancies, the technology has often faltered when applied to solid tumours (*Kandra et al., 2022*) – due to inherent factors such as hostile microenvironments and tumour heterogeneity (*Guzman et al., 2023*). Additionally, acute toxicities have been observed as a result of CAR-T therapy due to the presence of tumour

associated antigens on healthy cells. In the study by Johnson (2023) contrasting the high rate of remission, 33% of patients experienced immune effector cell-associated neurotoxicity syndrome, enveloping "*encephalopathy, memory loss, seizures, impaired speech, tremor, headache, language disturbance, and motor weakness*". Prior to implementing this technology into society, these complications must undergo further review. Kandra et al. (2022) reported the urgency of adapting genetic engineering approaches in order to counter current issues. Strategies to improve CAR-T therapy include modulating CAR activity to target multiple antigens and prevent toxicity, improving metabolic function of CAR-T cells increasing longevity of the cell whilst eliminating target cells, and enhancing CAR-T cells to secrete pro-inflammatory cytokines to protect the cell within the hostile, immunosuppressive microenvironment of solid tumours – among others. Overall, Kandra et al. (2022) has reviewed the positive and negative outcomes amounted from novel research in CAR-T cell therapy. Upon examination it is clear from high remission rates that CAR-T therapy is a promising technology, with applications in cancer treatment including lung cancer. However, before standardisation in the medical scene, limitations concerning ineffectiveness against solid tumours, as well as side-effects such as cytotoxicity and neurotoxicity must be addressed. Using strategies ensuing subsequent medical investigation, scientists and researchers can progress biological understanding of CAR-T cell therapy, preserving human life for the overarching benefit of society.

Evaluation

The sources analysed in this investigation are prime examples of communication and collaboration, and application and limitation, respectively. Initially, a meta-analysis of 52 studies from various databases, assessing CAR-T cell therapy in haematological malignancies and solid tumours, amounted in explicit results as reference for impending studies. Manufacturing recommendations were also established, with the potential of increasing treatment affordability, hence, preserving human life. Although Yu & Hua (2019) did not exercise direct communication between separate parties, the synthesis of sources from a wide range of locations verified scientific results creating an outcome advantageous for society. Additionally, a report reviewing the applications and limitations of CAR-T therapy in cancers including lung cancer. Results displayed that although CAR-T therapy is a promising technology with several applications, outstanding limitations such as cytotoxicity and neurotoxicity must be considered and medically reviewed before general standardisation. The source contained explicit discussion of applications and limiting factors of CAR-T therapy, proving itself an excellent example of this concept.

Conclusion

Overall, CAR-T cell therapy, devised via the engineering of T-Cells, is an auspicious prospect among contemporary cancer treatments, with remission-inducing abilities that supersede conventional technologies. Research assimilated from a range of sources has suggested its proficiency, and also new and improved means of manufacturing. However, a report reviewing the applications and limitations of the technology suggest further research prior to clinical integration.

[1482 Words – excluding bracketed in-text referencing]

0278-021
References

1. Aubusson, K. et al. (2023) *Why is cancer so hard to cure*. [online] Available at: <https://www.smh.com.au/national/why-is-cancer-so-hard-to-cure-20230626-p5djiw.html> [Accessed 22 February 2024]
2. CDC (2024) *Leading causes of death*. [online] Available at: <https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm> [Accessed 21 February 2024]
3. Cooper, G. M. (2000) *The Cell: A Molecular Approach. 2nd Edition.* [online] Available at: <https://www.ncbi.nlm.nih.gov/books/NBK9963/> [Accessed 21 February 2024]
4. Faguet, G. B. (2014) *A brief history of cancer: Age-old milestones underlying our current knowledge database*. [online] Available at: <https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.29134#> [Accessed 21 February 2024]
5. Guzman, G. et al. (2023) *CAR-T Therapies in Solid Tumors: Opportunities and Challenges*. [online] Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110629/> [Accessed 26 February 2024]
6. Johnson, P. C. et al. (2023) *Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy*. [online] Available at: <https://ashpublications.org/bloodadvances/article/7/14/3541/495093/Longitudinal-patient-reported-outcomes-in-patients> [Accessed 28 February 2024]
7. Kandra, P. (2022) *Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer*. [online]. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201083/> [Accessed 27 February 2024]
8. National Cancer Institute (2021) *What is cancer?* [online] Available at: <https://www.cancer.gov/about-cancer/understanding/what-is-cancer> [Accessed 21 February 2024]
9. National Cancer Institute (2022) *CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers.* [online] Available at: <https://www.cancer.gov/about-cancer/treatment/research/car-t-cells#> [Accessed 23 February 2024]
10. Yu, W; Hua, Z. (2019) *Chimeric Antigen Receptor T-cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety—A Systematic Review with Meta-Analysis*. [online] Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356949/> [Accessed 28 February 2024]